Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 11.64B | 10.53B | 9.56B | 8.60B | 6.35B |
Gross Profit | 6.74B | 6.52B | 5.95B | 5.25B | 4.04B |
EBITDA | 3.39B | 2.97B | 3.09B | 3.10B | 2.41B |
Net Income | 2.47B | 1.88B | 2.08B | 2.40B | 1.79B |
Balance Sheet | |||||
Total Assets | 24.99B | 22.52B | 22.37B | 21.06B | 16.98B |
Cash, Cash Equivalents and Short-Term Investments | 3.14B | 2.47B | 2.48B | 2.87B | 2.39B |
Total Debt | 4.44B | 3.40B | 4.48B | 3.65B | 2.39B |
Total Liabilities | 8.47B | 7.24B | 8.16B | 7.61B | 5.64B |
Stockholders Equity | 16.47B | 15.16B | 14.14B | 13.39B | 11.24B |
Cash Flow | |||||
Free Cash Flow | 1.28B | 1.93B | 245.79M | 1.49B | 1.31B |
Operating Cash Flow | 1.90B | 2.42B | 1.92B | 2.12B | 1.78B |
Investing Cash Flow | -2.00B | -515.75M | -2.58B | -2.05B | -2.05B |
Financing Cash Flow | 29.96M | -1.89B | 464.49M | -195.08M | 899.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | HK$33.37B | 15.83 | 12.65% | 2.77% | 10.56% | -13.58% | |
51 Neutral | $7.84B | -0.18 | -41.53% | 2.28% | 22.72% | -1.87% | |
― | £2.00B | 5.38 | 48.58% | ― | ― | ― | |
― | $3.88B | 7.03 | 21.02% | 3.77% | ― | ― | |
― | $4.09B | 14.35 | 10.01% | 2.78% | ― | ― | |
― | $4.78B | 13.62 | 15.72% | 3.94% | ― | ― | |
― | €3.36B | 9.23 | 5.89% | ― | ― | ― |
Grand Pharmaceutical Group Limited has announced that its board of directors will hold a meeting on August 19, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
Grand Pharmaceutical Group Limited announced a restructuring of its shareholding, with Outwit Investments Limited acquiring additional shares from East Ocean Capital, increasing its stake to 53.42% of the company’s total issued share capital. This internal restructuring, involving entities ultimately controlled by Beijing Huachuang, does not change the ultimate control of the company, and a waiver was obtained to avoid a general offer under the Hong Kong Code on Takeovers and Mergers.
Grand Pharmaceutical Group Limited has announced that its investigational radionuclide-drug conjugate, TLX591, for treating prostate cancer has received implied approval from China’s National Medical Products Administration to join an international Phase III clinical trial. This trial, involving over 500 patients across multiple countries, aims to evaluate the efficacy and safety of TLX591 in combination with standard care. The product, developed in collaboration with Telix Pharmaceuticals, offers a shorter treatment cycle and improved safety profile compared to existing therapies, potentially redefining the treatment standard for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Grand Pharmaceutical Group Limited has entered into a Business Collaboration Agreement with the Sirtex Group to jointly develop new radiopaque pharmaceutical products. This collaboration aims to leverage both companies’ expertise and resources, potentially enhancing their global presence and market opportunities by sharing R&D capabilities, resources, and technical knowledge.
Grand Pharmaceutical Group Limited announced the first commercial prescription of its nasal spray product, OC-01, for treating dry eye disease in Mainland China. This product, which is the first of its kind globally, offers a new treatment option for dry eye patients by increasing tear secretion through a nasal spray, potentially improving patient compliance compared to traditional eye drops. The company views ophthalmology as a strategic development area and aims to strengthen its market position with innovative products and a robust marketing network.
Grand Pharmaceutical Group Limited announced that its associate company, Sirtex Medical Pty Ltd, received early FDA approval for a new indication of its SIR-Spheres® Y-90 resin microsphere injection, now approved for treating unresectable hepatocellular carcinoma (HCC). This approval highlights the company’s strong clinical registration capabilities and supports its strategy to expand its nuclear medicine offerings globally, reinforcing its leadership in the industry. The product, which has been widely adopted and recognized for its effectiveness, is expected to enhance the company’s market position and provide significant growth opportunities.
Grand Pharmaceutical Group Limited announced the completion of patient enrollment for its Phase III clinical trial of CBT-001, an innovative ophthalmic drug for treating pterygium. This milestone is significant for the company’s strategic focus on ophthalmology, as CBT-001 has shown promising results in earlier trials and addresses a major unmet need in pterygium treatment. The company holds exclusive rights to produce and commercialize CBT-001 in several regions, enhancing its competitive edge in the market. Additionally, Grand Pharmaceutical is expanding its innovative product pipeline and strengthening its marketing network to support sustainable growth.
Grand Pharmaceutical Group Limited announced that its innovative ophthalmic product, GPN01768, has been approved for commercialization by the Pharmaceutical Administration Bureau of Macao, China. This approval is expected to pave the way for further approvals in the Guangdong-Hong Kong-Macao Greater Bay Area and Mainland China, addressing the urgent clinical need for effective treatment of Demodex blepharitis, a common ophthalmic disease. The company has made significant progress in its research and development pipeline, aiming to strengthen its position in the ophthalmology sector and expand its market presence with a series of innovative products.
Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Chengdu has obtained a Class A ‘Radiation Safety License’ and will soon commence operations. This development marks a significant milestone in the company’s strategy to become a global leader in nuclear medicine, enhancing its capabilities in isotope production and nuclear medicine preparation. The base, with an investment of over RMB 3 billion, features advanced technological breakthroughs and aims to set new safety benchmarks in the industry. It will support the company’s global strategy by providing a closed-loop system for R&D, production, and sales, and will contribute to the development of high-value nuclear medicine products, strengthening its position in the global market.